Real‑world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis

Graf,Rebecca; Kreye,Gudrun; Pecherstorfer,Martin; Singer,Josef

doi:10.3892/ol.2025.15119

Real‑world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis

Authors:
- Rebecca Graf
- Gudrun Kreye
- Martin Pecherstorfer
- Josef Singer
View Affiliations

Affiliations: Karl Landsteiner University of Health Sciences, A-3500 Krems, Austria
Published online on: May 30, 2025 https://doi.org/10.3892/ol.2025.15119
Article Number: 373
Copyright: © Graf et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic myeloid leukaemia (CML) is characterized by the genetic alteration BCR‑ABL. The introduction of the tyrosine kinase inhibitor (TKI), imatinib, in 2002, inhibiting BCR‑ABL signalling, has revolutionized CML therapy and is still one of the preferred first‑line treatment options. The present study aimed to assess possible differences in older and younger patients with BCR‑ABL‑positive CML treated with imatinib, with regards to remission rates, remission depth, remission duration or discontinuation of imatinib due to adverse events. Data was collected retrospectively from the records of patients with BCR‑ABL‑positive CML treated with imatinib at the University Hospital Krems from January 2011 to December 2021. Exclusion criteria included the administration of other first line therapies besides imatinib, an age of <18 years or other cancer types. Overall, 22 patients were included in the present study and separated into two age groups: <60 and ≥60 years old. The results revealed no significant difference in remission rates, remission depth, progression‑free survival or overall survival between these age groups. In conclusion, the findings indicate that the TKI, imatinib, is highly effective and well tolerated in both younger and older patients with CML. However, further studies with larger patient groups and the inclusion of newer TKIs are required.

View Figures

View References

1	Hehlmann R, Hochhaus A and Baccarani M; European LeukemiaNet, : Chronic myeloid leukaemia. Lancet. 370:342–350. 20074 View Article : Google Scholar : PubMed/NCBI
2	Hoglund M, Sandin F and Simonsson B: Epidemiology of chronic myeloid leukaemia: An update. Ann Hematol. 94 (Suppl 2):S241–S247. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ning L, Hu C, Lu P, Que Y, Zhu X and Li D: Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: A population-based epidemiologic study. Exp Hematol Oncol. 9:292020. View Article : Google Scholar : PubMed/NCBI
4	Kurzrock R, Gutterman JU and Talpaz M: The molecular genetics of philadelphia chromosome-positive leukemias. N Engl J Med. 319:990–998. 1988. View Article : Google Scholar : PubMed/NCBI
5	Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, et al: Imatinib in philadelphia chromosome-positive chronic phase cml patients: Molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol. 73:249–255. 2003. View Article : Google Scholar : PubMed/NCBI
6	Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, et al: Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 22:43–69. 2024. View Article : Google Scholar : PubMed/NCBI
7	Mahon FX and Etienne G: Deep molecular response in chronic myeloid leukemia: The new goal of therapy? Clin Cancer Res. 20:310–322. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rinaldi I and Winston K: Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review. J Blood Med. 14:261–277. 2023. View Article : Google Scholar : PubMed/NCBI
9	Kennedy BJ: Hydroxyurea therapy in chronic myelogenous leukemia. Cancer. 29:1052–1056. 1972. View Article : Google Scholar : PubMed/NCBI
10	Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, et al: Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 26:185–192. 2015. View Article : Google Scholar : PubMed/NCBI
11	Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, et al: Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV. Blood. 126:42–49. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W and Kantarjian H: Effects of age on prognosis with imatinib mesylate therapy for patients with philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 98:1105–1113. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, et al: Safety and efficacy of imatinib in cml over a period of 10 years: Data from the randomized cml-study IV. Leukemia. 29:1123–1132. 2015. View Article : Google Scholar : PubMed/NCBI
14	Adattini JA, Gross AS, Wong Doo N and McLachlan AJ: Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An australian experience. Pharmacol Res Perspect. 10:e010052022. View Article : Google Scholar : PubMed/NCBI
15	Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, et al: Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML working party. Blood. 117:5591–5599. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, et al: Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 34:2333–2340. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, et al: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: Enestnd 10-year analysis. Leukemia. 35:440–453. 2021. View Article : Google Scholar : PubMed/NCBI